Study on the Correlation Between Gene Mutation and TCM Syndrome Types in Metastatic Colorectal Cancer
December 8, 2020 updated by: Shanghai University of Traditional Chinese Medicine
To explore the correlation between gene mutations of metastatic colorectal cancer and TCM syndrome types based on Second-generation sequencing technology.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A clear pathological diagnosis is a patient with colorectal cancer;
- Have complete TNM staging information;
- There is a clear diagnosis of the location and time of metastasis;
- Age ≥18 years old, ≤80 years old, male or female;
- There is a clear time for the first treatment with Chinese medicine;
- Patients who can receive long-term follow-up. -
Exclusion Criteria:
- Patients with colorectal cancer diagnosed pathologically as adenosquamous carcinoma, squamous cell carcinoma, carcinoid, small cell carcinoma, malignant lymphoma, etc.;
- Patients with double cancer, multiple or metastatic colorectal cancer;
- Combined with severe acute and chronic diseases that may affect treatment and prognosis, such as myocardial infarction, stroke, severe renal insufficiency and mental illness;-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TCM Syndrome Types
Traditional Chinese Medicine
|
Chinese medicine prescription
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: 2 years
|
OS
|
2 years
|
|
Progression Free Survival
Time Frame: 2 years
|
PFS
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 30, 2020
Primary Completion (Anticipated)
August 31, 2022
Study Completion (Anticipated)
August 31, 2022
Study Registration Dates
First Submitted
November 20, 2020
First Submitted That Met QC Criteria
December 8, 2020
First Posted (Actual)
December 9, 2020
Study Record Updates
Last Update Posted (Actual)
December 9, 2020
Last Update Submitted That Met QC Criteria
December 8, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHSLCZDZK 03701
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gene Mutation-Related Cancer
-
Mayo ClinicRecruitingCancer | Cancer Gene Mutation | PAN Gene MutationUnited States
-
University Medical Center NijmegenRecruitingOvarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene MutationNetherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
-
University of VirginiaActive, not recruitingReal-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAFUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs...RecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingCancer Gene MutationItaly
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
Columbia UniversityRecruitingCancer | Insulin Resistance | MTOR Gene Mutation | PI3K Gene Mutation | AKT Gene MutationUnited States
Clinical Trials on Traditional Chinese Medicine
-
Henan University of Traditional Chinese MedicineUnknownCommunity-acquired PneumoniaChina
-
Qianfoshan HospitalNot yet recruitingHepatic Encephalopathy | Cirrhosis, Liver | Portosystemic ShuntChina
-
Xiyuan Hospital of China Academy of Chinese Medical...Beijing Municipal Science & Technology CommissionUnknownAdvanced Colorectal Cancer | Traditional Chinese MedicineChina
-
Shengjing HospitalRecruitingPlasma Cell MastitisChina
-
Taipei Veterans General Hospital, TaiwanWithdrawnRheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Dry Eye Syndrome | Sjögren's Syndrome | Ankylosing SpondylitisTaiwan
-
National Center for Complementary and Integrative...CompletedTemporomandibular Joint DisordersUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingDiarrhea Caused by Antitumor DrugsChina
-
Sheng LiuUnknownRecurrence | Overall Survival | Progression-Free-SurvivalChina
-
Chinese University of Hong KongUniversity of Maryland; National Center for Complementary and Integrative Health...CompletedIrritable Bowel SyndromeChina
-
Xiyuan Hospital of China Academy of Chinese Medical...Unknown